

Giuseppe M C Rosano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9107235/publications.pdf>

Version: 2024-02-01

59
papers

25,284
citations

136950

32
h-index

123424

61
g-index

62
all docs

62
docs citations

62
times ranked

27434
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	2.2	13,008
2	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	7.1	5,272
3	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
4	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	3.8	517
5	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	7.1	455
6	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
7	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	4.1	267
8	Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-15.	4.0	237
9	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2885-2896.	2.8	198
10	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	7.1	182
11	Exercise-Induced Skeletal Muscle Remodeling and Metabolic Adaptation: Redox Signaling and Role of Autophagy. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 154-176.	5.4	157
12	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 306-317.	4.1	125
13	Heart Failure in Patients with Diabetes Mellitus. <i>Cardiac Failure Review</i> , 2017, 03, 52.	3.0	122
14	Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. <i>Cardiovascular Diabetology</i> , 2003, 2, 16.	6.8	111
15	Under-representation of elderly and women in clinical trials. <i>International Journal of Cardiology</i> , 2017, 232, 216-221.	1.7	105
16	Effect of age and sex on efficacy and tolerability of β^2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016, 353, i1855.	6.0	95
17	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.	1.7	88
18	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. <i>International Journal of Cardiology</i> , 2013, 163, 320-325.	1.7	77

#	ARTICLE	IF	CITATIONS
19	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	7.1	74
20	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 909-915.	1.7	67
21	The mitochondrial metabolic reprogramming agent trimetazidine as an "exercise mimetic"™ in cachectic C26-bearing mice. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 954-973.	7.3	63
22	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 220, 595-601.	1.7	59
23	Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 449-457.	7.3	44
24	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1844-1854.	7.1	42
25	A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. <i>American Heart Journal</i> , 2012, 163, 1019-1023.	2.7	41
26	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	2.2	40
27	The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. <i>FEBS Journal</i> , 2013, 280, 5094-5108.	4.7	39
28	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	3.0	39
29	Trimetazidine improves exercise performance in patients with peripheral arterial disease. <i>Pharmacological Research</i> , 2011, 63, 278-283.	7.1	37
30	Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. <i>Heart Failure Clinics</i> , 2013, 9, 285-290.	2.1	37
31	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149.	2.7	34
32	Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. <i>Advances in Therapy</i> , 2009, 26, 455-461.	2.9	31
33	Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice. <i>Oncotarget</i> , 2017, 8, 113938-113956.	1.8	29
34	Animal models of cardiac cachexia. <i>International Journal of Cardiology</i> , 2016, 219, 105-110.	1.7	27
35	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 197-204.	2.7	25
36	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , 2017, 19, 449-456.	7.1	19

#	ARTICLE	IF	CITATIONS
37	Sodiumâ€“Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. <i>Cardiac Failure Review</i> , 2020, 6, e31.	3.0	17
38	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 682-692.	1.8	15
39	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 97-103.	3.0	14
40	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	3.9	13
41	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	7.1	11
42	Disclosure of negative trial results. A call for action. <i>International Journal of Cardiology</i> , 2015, 198, 47-48.	1.7	8
43	Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4173-4191.	5.4	7
44	Inter-twinning relationship between heart failure and atrial fibrillation. <i>Heart</i> , 2020, 106, 1125-1126.	2.9	6
45	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	3.0	6
46	The Metabolic Syndrome in Women. <i>Women's Health</i> , 2006, 2, 889-898.	1.5	5
47	Clinical Trial Design, Endpoints, and Regulatory Requirements. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 67-78.	1.8	5
48	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	3.0	5
49	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 331-339.	2.1	4
50	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 745-754.	1.0	4
51	Adaptive licensing â€” A way forward in the approval process of new therapeutic agents in Europe. <i>International Journal of Cardiology</i> , 2015, 184, 568-569.	1.7	3
52	2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 331-332.	3.0	3
53	Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 37-38.	3.0	2
54	Incretin-based therapy for type 2 diabetes: A real class effect?. <i>International Journal of Cardiology</i> , 2017, 227, 141-142.	1.7	2

#	ARTICLE	IF	CITATIONS
55	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e89-e90.	3.0	2
56	Survival to intensive care unit discharge among in-hospital cardiac arrest patients by applying audiovisual feedback device. <i>ESC Heart Failure</i> , 2021, , .	3.1	2
57	Adaptive licensing “ A way forward in the approval process of new therapeutic agents in Europe. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 1, 1-2.	1.0	1
58	From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 83-85.	3.0	1
59	Sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e9-e10.	3.0	0